

Zhi-Qin Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2841085/publications.pdf>

Version: 2024-02-01

23
papers

1,874
citations

516215

16
h-index

752256

20
g-index

23
all docs

23
docs citations

23
times ranked

3640
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. <i>Cancer</i> , 2011, 117, 4623-4632.	2.0	624
2	Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. <i>Clinical Cancer Research</i> , 2013, 19, 657-667.	3.2	250
3	Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: The MD Anderson Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 332-339.	0.4	141
4	Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. <i>Oncologist</i> , 2015, 20, 127-133.	1.9	109
5	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	1.0	108
6	The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2013, 8, e77117.	1.1	106
7	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. <i>Genome Biology</i> , 2017, 18, 98.	3.8	97
8	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 1352-1361.	2.9	81
9	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4578-4591.	3.2	70
10	Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome. <i>PLoS ONE</i> , 2013, 8, e65144.	1.1	50
11	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50
12	High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. <i>Clinical Colorectal Cancer</i> , 2016, 15, e1-e7.	1.0	41
13	Modeling of Patient-Derived Xenografts in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1435-1442.	1.9	40
14	A <i>NOTCH1</i> gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. <i>International Journal of Cancer</i> , 2016, 138, 195-205.	2.3	35
15	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 4051-4058.	0.7	32
16	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. <i>Cancer</i> , 2015, 121, 2968-2975.	2.0	22
17	Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2014, 14, 660.	1.1	14
18	Genomic classifiers (ColoPrint/MSI-Print) predict outcome and chemotherapy benefit in stage II and III colon cancer patients. <i>Journal of Clinical Oncology</i> , 2013, 31, 378-378.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Increased gene copy number and amplification of FGF2 and FGFR1 in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 402-402.	0.8	1
20	Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.. Journal of Clinical Oncology, 2018, 36, 3549-3549.	0.8	1
21	Molecular characteristics of complete PTEN loss in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 389-389.	0.8	0
22	Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 452-452.	0.8	0
23	Meat consumption and BRAF mutation status in colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15135-e15135.	0.8	0